Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI-Reference-Cited by-同舟云学术

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Published:2015-09 Issue:3 Volume:89 Page:357-359
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Klempner Samuel J.,Bazhenova Lyudmila A.,Braiteh Fadi S.,Nikolinakos Petros G.,Gowen Kyle,Cervantes Claudia M.,Chmielecki Juliann,Greenbowe Joel R,Ross Jeffrey S.,Stephens Philip J.,Miller Vincent A.,Ali Siraj M.,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

2. Acquired resistance to TKIs in solid tumours: learning from lung cancer;Camidge;Nat. Rev. Clin. Oncol.,2014

3. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches;Drilon;Clin. Cancer Res.,2015

4. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas;Drilon;Cancer Discov.,2013

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report;Anti-Cancer Drugs;2023-06-02

2. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis;Journal of Cancer Research and Clinical Oncology;2023-06-01

3. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis;2023-04-24

4. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers;Clinical Cancer Research;2023-03-30

5. HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons;Anti-Cancer Drugs;2023-01-24